Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farxiga in Hyperfiltering T2DM
NCT02911792Phase 4Completed
- Sponsor
- UT Health San Antonio
- Start
- Dec 2016
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by UT Health San Antonio. Primary endpoint: Glomerular Filtration Rate Change After Treatment at 4 months. Started Dec 2016; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02911792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911792.